Pipeline Moves: Novartis Phase I/Ib cancer trial terminates, further study chances drop
The Clinical Trials Arena team also investigate assets in radiculopathy, solid tumours, radicular pain, autoimmune disorders and inflammation.
By
Pharma Insights
Latest in
Pharma Insights
Pipeline Moves: Phase II gout trial termination slashes advancement prospects
We also review assets in allergic rhinitis, anorexia, paroxysmal nocturnal haemoglobinuria, and polyomavirus infections.
By
Pipeline Moves: Phase II essential tremor trial completes, advancement prospects jump
Clinical Trials Arena team also look into trials in glioblastoma multiforme, open-angle glaucoma, and hives.
By
Pipeline Moves: Phase II head and neck cancer study terminated, advancement shot drops
The Clinical Trials Arena team also review assets in lower limb muscle spasticity, diabetic foot ulcers, and low back pain.
By
Pipeline Moves: Novartis suspends platform trial, advancement shot of four blood cancer assets drop
We also review primary systemic amyloidosis, tuberculosis, and uterine leiomyoma trial terminations.
By
Pipeline Moves: Nektar terminates Phase I/II cancer trial, further study shot in seven indications drop
Further investigations of peanut allergy and traumatic brain injury assets also reviewed after study terminations.
By
Pipeline Moves: Further study shot dive for hepatitis B, pancreatic cancer assets after trials end early
The Clinical Trials Arena team also study assets in endometrial cancer, DiGeorge Syndrome, and prurigo nodularis.
By
Pipeline Moves: Further study shot of three cancer assets reviewed after early phase terminations
Early phase study completions in Huntington’s disease and obstructive sleep apnoea are also reviewed.
By